SPARK team launches clinical COVID-19 biomarker study

SPARK team launches clinical COVID-19 biomarker study

Posted on March 17th, 2021

A SPARK group is now enrolling patients and healthy controls in a clinical study at Stanford to understand the impact of SARS-CoV-2 on cardiovascular and immune systems.

Led by SPARK co-director Kevin Grimes, the research study will measure levels of specific cardiovascular and immune biomarkers believed to be impacted by SARS-CoV-2 infection.

By measuring these indicators, the team hopes to better predict the clinical course of COVID-19, help predict which patients are likely to get worse, help guide treatment strategies, and inform development of new therapies. Participants must be 18-80 years old and have taken a SARS-CoV-2 RNA test within the last 5 days, with confirmed positive or negative results.

For more information on the study and enrollment eligibility, visit the study’s page here.